GlassScriptPhysician profile
Connor James Thompson
NPI 1598499865
$4,463.48
in general payments reported to CMS, 2019-2025
30 companies · $3,346 in 2025
The $3,346 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,117 · 2025: $3,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,376 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,375.99 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $565.58 | 2024-2025 | |
| Lilly USA, LLC | $513.06 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $346.71 | 2024-2025 | |
| Pfizer INC. | $310.17 | 2025 | |
| Lundbeck LLC | $292.87 | 2024-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $239.72 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $224.36 | 2024-2025 | |
| Emd Serono, INC. | $206.13 | 2024-2025 | Mavenclad |
| Biogen, INC. | $204.93 | 2024-2025 | Vumerity, Tysabri, Avonex |
| Tg Therapeutics, INC. | $179.29 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $166.66 | 2024-2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $158.11 | 2024-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Neurocrine Biosciences, INC. | $126.83 | 2025 | |
| Argenx US, INC. | $115.72 | 2024-2025 | Vyvgart Hytrulo |
| Neurelis, INC. | $107.13 | 2025 | Valtoco |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $87.23 | 2024-2025 | |
| Ucb, INC. | $82.68 | 2024-2025 | Briviact, Nayzilam |
| Amgen INC. | $82.67 | 2025 | Uplizna |
| Tanabe Pharma America, INC. | $71.65 | 2024-2025 | Radicava |
| Ipsen Biopharmaceuticals, INC | $60.85 | 2025 | Dysport |
| Alnylam Pharmaceuticals INC. | $58.97 | 2025 | Amvuttra |
| Vanda Pharmaceuticals INC. | $52.14 | 2025 | Ponvory |
| Sk Life Science, INC. | $51.87 | 2025 | |
| Insightec,INC | $28.26 | 2025 | Exablate |
| Genentech USA, INC. | $26.66 | 2025 | Ocrevus Zunovo |
| Life Molecular Imaging LTD | $24.40 | 2025 | Neuraceq |
| Biotronik Nro, INC. | $21.87 | 2025 | Prospera |
| Springworks Therapeutics, INC. | $20.26 | 2025 | Gomekli |
| Kyowa Kirin, INC. | $18.93 | 2024 | Nourianz |
| Genzyme Corporation | $17.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connor Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.